NCT03239626Active, not recruiting
Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer
Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer: a Prospective Exploratory Trial (POHIM_RT Trial)
Source: ClinicalTrials.gov · Last updated 3 Jan 2025
Brief summary (registry, in English)
To investigate the acute toxicities, late toxicities, and treatment results when the early cervical cancer patients are treated by hypofractionated intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after radical hysterectomy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 2 Aug 2017
- Start date
- 31 Aug 2017
- Primary completion date
- 28 Apr 2025
- Lead sponsor
- Samsung Medical Center
- Diseases
- Cervical cancer
- NCT number
- NCT03239626
What you commit to
- Study type: Interventional
- Participants enrolled: 120
- From 31 Aug 2017 to the primary completion date, 28 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- positive tumor involvement on resection margin
- previous history of pelvic radiotherapy
- neoadjuvant chemotherapy was done
- previous history of other carcinoma except for thyroid cancer, skin cancer, in situ carcinoma on cervix
Other illness
- more than 3 months after radical surgery for cervical cancer
Other
- positive pelvic lymph node metastasis
- positive distant metastasis (including retroperitoneal lymph node metastasis)
- positive parametrial invasion
Who the study is looking for
- histologically confirmed cervical cancer
- radical hysterectomy and pelvic lymph node dissection was done
- histologically indicated adjuvant radiotherapy ( more than one as below)
- tumor size ≥4 cm
- positive lymphovascular invasion
- more than half stromal invasion depth
- ECOG performance status 0 or 1
- Bone marrow function: granulocyte ≥1.0 x 1000/µl, platelet ≥30 x 1000/µl, hemoglobin ≥10 g/dl
Age in the registry: 20 years to 70 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.